Anxiolytic properties of the selective, non-peptidergic CRF1 antagonists, CP154,526 and DMP695: A comparison to other classes of anxiolytic agent

Neuropsychopharmacology

Volumn 25, Issue 4, 2001, Pages 585-600

  Millan, Mark J ^a,b   Brocco, Mauricette ^a   Gobert, Alain ^a   Dorey, Gilbert ^a   Casara, Patrick ^a   Dekeyne, Anne ^a  

^a INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^b INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

5 HT1A receptors; 5 HT2C receptors; Anxiety; Benzodiazepines; CRF1 receptors

Indexed keywords

1,2,3,5 TETRAHYDRO 5 METHYL 1 (3 PYRIDYLCARBAMOYL)PYRROLO[2,3 F]INDOLE; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; ANXIOLYTIC AGENT; BENZODIAZEPINE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CHLORDIAZEPOXIDE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DMP 695; DOPAMINE; FLESINOXAN; MONOAMINE; N (2 CHLORO 4,6 DIMETHYLPHENYL) 1 [1 METHOXYMETHYL (2 METHOXYETHYL] 6 METHYL 1H 1,2,3 TRIAZOLO[4,5 C]PYRIDIN 4 AMINE)MESYLATE; NORADRENALIN; SEROTONIN; SEROTONIN 1A RECEPTOR; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIALYSATE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; FRONTAL CORTEX; LOCOMOTION; MALE; MAZE TEST; MONOAMINE RELEASE; NONHUMAN; PRIORITY JOURNAL; PUNISHMENT; RAT; SOCIAL INTERACTION; TRANQUILIZING ACTIVITY; VOCALIZATION;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; EXTRACELLULAR SPACE; INTERPERSONAL RELATIONS; MALE; MUSCULOSKELETAL EQUILIBRIUM; NOREPINEPHRINE; PYRIDINES; PYRIMIDINES; PYRROLES; RATS; RATS, WISTAR; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; SEROTONIN; VOCALIZATION, ANIMAL;

EID: 0034850479     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0893-133X(01)00244-5     Document Type: Article

References (98)

1. The effects of CRF and α-helical CRF on anxiety in normal and hypophysectomized rats
2. 1A receptors in the median raphe nucleus and dorsal hippocampus may mediate anxiolytic and anxiogenic behaviours respectively
3. Chronic administration of the selective corticotropin-releasing factor 1 receptor antagonist CP-154,526: Behavioral, endocrine and neurochemical effects in the rat
4. 1) receptor antagonist
5. 2 antagonists and benzodiazepines: Conflict and drug discrimination studies
6. Blockade of CRF-induced excitation of locus coeruleus cell firing by CP-154,526, a non-peptide antagonist of central CRF receptors
7. Corticotropin releasing factor (CRF) receptor antagonist blocks activating and "anxiogenic" actions of CRF in the rat
8. 3) receptor antagonists increase rates of punished responding in rats
9. 1 receptor mRNA expression
10. Noradrenergic neural substrates for anxiety and fear: Clinical associations based on preclinical research
11. 1)-like immunoreactivity in the mouse brain: Light microscopy analysis using an antibody directed against the C-terminus
12. 1A antagonist, WAY 100635
13. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1
14. Persistent elevations of cerebrospinal fluid concentrations of cortocotropin-releasing factor in adult nonhuman primates exposed to early-life stressors: Implications for the pathophysiology of mood and anxiety disorders
15. 1A receptor
16. Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: Effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity
17. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress
18. 1A receptor ligand, S15535, displays anxiolytic-like effects in the social interaction and Vogel models and suppresses dialysate levels of 5-HT in the dorsal hippocampus of freely-moving rats: A comparison with other anxiolytic agents
19. Corticotropin-releasing factor receptors: Physiology, pharmacology, biochemistry and role in central nervous system and immune disorders
20. Cloning and characterization of human urocortin
21. Corticotropin-releasing factor has an anxiogenic action in the social interaction test
22. The CRF receptor 1 antagonist, antalarmin, decreases anxiety as assessed by the shock-probe burying test in rats
23. Pyrazole-(1,5-a)-pyrimidine CRF antagonists: Synthesis and structure-activity relationships
24. Corticotropin releasing factor (CRF) receptor modulators: Progress and opportunities for new therapeutic agents
25. 2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
26. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: More than 30 years of research
27. 2 receptor subtype antagonists in rat and mouse models of anxiety
28. Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents
29. Characterization of corticotropin-releasing factor receptor subtypes
30. In vitro and in vivo characterizaton of CP-154,526, a non-peptide CRF1 receptor antagonist with partial agonist properties
31. Anxiolytic effect of the CRF antagonist, CP-154,526, in a light/dark anxiety test in mice
32. 1 receptor antagonist
33. 1 receptor selective antagonist
34. Corticotropin-releasing factor antagonist reduces emotionality in socially defeated rats via direct neurotropic action
35. 2, receptors mediate anxiogenic-like behavior
36. Effect of corticotropin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in the hippocampus and prefrontal cortex of rats in vivo
37. Differential effects of two corticotropin-releasing factor antagonists on conditioned defeat in male syrian hamsters (Mesocricetus auratus)
38. 1A receptor agonist flesinoxan increases aversion in a model of panic-like anxiety in rats
39. 2C receptor agonists and fluoxetine in a model of panic-like anxiety in rats
40. Altered anxiety and weight gain in cortocotropin-releasing hormone-binding protein-deficient mice
41. The role of afferents to the locus coeruleus in the handling stress-induced increase in the release of noradrenaline in the medial prefrontal cortex: A dual-probe microdialysis study in the rat brain
42. 1 receptor antagonist R121919 is dependent on the innate emotionality in rats
43. 1 receptor antagonist, CP 154,526, in the separation-induced vocalization anxiolytic test in the rat pups
44. 2B receptor antagonist with anxiolytic-like properties
45. 2C receptor antagonist
46. 1A receptor ligands in a modified Geller-Seifter conflict model in the rat
47. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus
48. Differential behavioral effects of chronic infusion of CRH1 and CRH2 receptor antisense oligonucleotides into the rat brain
49. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats
50. A non peptide corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity
51. Anxiogenic effect of corticotropin-releasing hormone in the dorsal periaqueductal grey
52. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats
53. A and 5-HT anxiolytics
54. The induction of pain: An integrative review
55. 1A receptors: II. Modulation of hippocampal serotonin release in relation to potential anxiolytic properties
56. Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: Relevance to the actions of antidepressant agents
57. 2-adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine
58. The role of corticotropin releasing factor in depressive illness: A critical review
59. Conditioned ultrasonic distress vocalizations in adult male rats as a behavioral paradigm for screening anti-panic drugs
60. Urocortin, a novel neuropeptide with anxiogenic-like properties
61. The role of mesoprefrontal dopamine neurons in the acquisition and expression of conditioned fear in the rat
62. Receptor binding, behavioral, and electrophysiological profiles of nonpeptide corticotropin-releasing factor subtype 1 receptor antagonists CRA1000 and CRA1001
63. Physiology and pharmacology of corticotropin-releasing factor
64. Discrete local application of corticotropin-releasing factor increases locus coeruleus discharge and extracellular norepinephrine in rat hippocampus
65. Distribution of corticotropin-releasing factor receptor mRNA expression in the rat brain and pituitary
66. Effects of corticotropin-releasing factor on brain serotonin activity
67. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: Differential roles of CRF receptors 1 and 2
68. The elevated plus-maze: Pharmacology, methodology and ethology
69. 1A receptor agonist, flesinoxan
70. Corticotropic-releasing hormone and serotonin interact in the human brainstem: Behavioral implications
71. Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses
72. 2 receptors in mediating foot-shock-induced ultrasonic vocalisation in adults rats
73. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain
74. Increased rates of punished responding produced by buspirone-like compounds in rats
75. The functional neuroanatomy of corticotropin-releasing factor
76. 1A receptor agonists 8-OH-DPAT, ipsapirone and buspirone in the rat
77. CP-154,526: A potent and selective nonpeptide antagonist of corticotropin releasing factor receptors
78. CRF receptor antagonist attenuates stress-induced noradrenaline release in the medial prefrontal cortex of rats
79. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats
80. Corticotropin-releasing hormone receptor (type I) antisense targeting reduces anxiety
81. The role of CRF receptor subtypes in stress-induced behavioural responses
82. The role of CRH2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia
83. Corticotropin-releasing factor administered into the locus coeruleus, but not the parabrachial nucleus, stimulates norepinephrine release in the prefrontal cortex
84. CRF receptor antagonist attenuates immobilization stress-induced norepinephrine release in the prefrontal cortex in rats
85. Corticotropin releasing factor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development
86. Behavioral effects of central administration of the novel CRF antagonist astressin in rats
87. Corticotopin-releasing hormone receptor subtypes and emotion
88. Overproduction of corticotropin-releasing factor in transgenic mice: A genetic model of anxiogenic behavior
89. Antagonism of corticotropin-releasing factor receptors in the locus coeruleus attenuates shock-induced freezing in rats
90. Injections of corticotropin-releasing factor into the periacqueductal grey enhance pavlovian fear conditioning
91. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1
92. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses
93. Corticotropin-releasing factor-containing axon terminals synapse onto catecholamine dendrites and may preferentially modulate other afferents in the rostral pole of the nucleus locus coeruleus in the rat brain
94. Reduced anxiety-related behaviour in CRH1 knockout mice following social defeat
95. 1A receptor agonist flesinoxan in panic disorder
96. Depression and anxiety: Role of the locus coeruleus and corticotropin-releasing factor
97. Design and syntheses of NBI 30545 and analogues as potent CRF receptor antagonists
98. Interactions of corticotropin-releasing factor with antidepressant and anxiolytic drugs: Behavioral studies with pigeons